G1T38, a novel, oral, potent and selective CDK4/6 inhibitor for the treatment of Rb competent tumors

被引：0
|
作者：
Sorrentino, Jessica A.
Bisi, John E.
Roberts, Patrick J.
Strum, Jay C.
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-2824
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2824
引用
收藏
页数：4
相关论文
共 50 条
  • [31] The novel potential of palbociclib (CDK4/6 inhibitor) in the treatment of triple-negative breast cancer
    Kashiwagi, Shinichiro
    Asano, Yuka
    Goto, Wataru
    Takada, Koji
    Takashima, Tsutomu
    Morisaki, Tamami
    Noda, Satoru
    Onoda, Naoyoshi
    Hirakawa, Kosei
    Ohira, Masaichi
    CANCER RESEARCH, 2017, 77
  • [32] The novel potential of palbociclib (CDK4/6 inhibitor) in the treatment of triple-negative breast cancer
    Asano, Yuka
    Kashiwagi, Shinichiro
    Goto, Wataru
    Takahashi, Katsuyuki
    Takashima, Tsutomu
    Noda, Satoru
    Onoda, Naoyoshi
    Tomita, Shuhei
    Hirakawa, Kosei
    Ohira, Masaichi
    CANCER RESEARCH, 2017, 77
  • [33] FCN-159: A novel, potent and selective oral inhibitor of MEK1/2 for the treatment of solid tumors
    Shu Lin
    Zhao, Xingdong
    Zhou, Zuwen
    Tan, Haohan
    Ling Chen
    Rui Tan
    Zhang, Weipeng
    Jiang, Lihua
    Li Linghu
    Jing Sun
    Zhou, Jiashu
    Te Li
    Song, Yunlong
    Wang, Weibo
    CANCER RESEARCH, 2020, 80 (16)
  • [34] Cdk4/6 inhibitor activity in metastatic bladder cancer cell lines is independently of RB1 status
    Castellano, D.
    Rubio, C.
    Lopez-Calderon, F.
    Segovia, C.
    Duenas, M.
    Martinez-Fernandez, M.
    Otero, I.
    Manneh, R.
    De Velasco, G.
    Paramio, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [35] G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer
    Andreano, Kaitlyn J.
    Wardell, Suzanne E.
    Baker, Jennifer G.
    Desautels, Taylor K.
    Baldi, Robert
    Chao, Christina A.
    Heetderks, Kendall A.
    Bae, Yeeun
    Xiong, Rui
    Tonetti, Debra A.
    Gutgesell, Lauren M.
    Zhao, Jiong
    Sorrentino, Jessica A.
    Thompson, Delita A.
    Bisi, John E.
    Strum, Jay C.
    Thatcher, Gregory R. J.
    Norris, John D.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (03) : 635 - 646
  • [36] G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer
    Kaitlyn J. Andreano
    Suzanne E. Wardell
    Jennifer G. Baker
    Taylor K. Desautels
    Robert Baldi
    Christina A. Chao
    Kendall A. Heetderks
    Yeeun Bae
    Rui Xiong
    Debra A. Tonetti
    Lauren M. Gutgesell
    Jiong Zhao
    Jessica A. Sorrentino
    Delita A. Thompson
    John E. Bisi
    Jay C. Strum
    Gregory R. J. Thatcher
    John D. Norris
    Breast Cancer Research and Treatment, 2020, 180 : 635 - 646
  • [37] First-in-human Phase 1 safety, PK, and PD study of the CDK4/6 inhibitor G1T28.
    Tiessen, Renger G.
    Roberts, Patrick J.
    Sorrentino, Jessica A.
    White, Hannah S.
    Makhuli, Karenann M.
    Bisi, John E.
    Strum, Jay C.
    van Hoogdalem, Ewoud-Jan
    Malik, Rajesh K.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [38] Utilizing genome-informed modeling to assess CDK4/6 inhibitor response in breast cancer patients, simulate clinical trials, and result in novel CDK4/6 inhibitor treatment for chordoma patients
    Yang, Mei
    Liu, Yuhan
    Hsueh, Yi-Ching
    Zhang, Qiangzu
    Fan, Yanhui
    Xu, Juntao
    Huang, Min
    Li, Xu
    Chen, Su
    Yang, Jianfei
    Niu, Gang
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [39] Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors
    Uzhachenko, Roman, V
    Bharti, Vijaya
    Ouyang, Zhufeng
    Blevins, Ashlyn
    Mont, Stacey
    Saleh, Nabil
    Lawrence, Hunter A.
    Shen, Chengli
    Chen, Sheau-Chiann
    Ayers, Gregory D.
    DeNardo, David G.
    Arteaga, Carlos
    Richmond, Ann
    Vilgelm, Anna E.
    CELL REPORTS, 2021, 35 (01):
  • [40] A novel CDK4/6 inhibitor combined with irradiation demonstrates potent anti-tumor efficacy in diffuse midline glioma
    Pengcheng Zuo
    Yaopeng Li
    Tantan Wang
    Xingyu Lin
    Zhen Wu
    Junting Zhang
    Xuebin Liao
    Liwei Zhang
    Journal of Neuro-Oncology, 2023, 163 : 159 - 171
12345